vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Talkspace, Inc. (TALK). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $63.0M, roughly 1.2× Talkspace, Inc.). On growth, Talkspace, Inc. posted the faster year-over-year revenue change (29.3% vs -36.9%). Over the past eight quarters, Talkspace, Inc.'s revenue compounded faster (17.8% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Talkspace, Inc. is an American company that provides online and mobile therapy services. Founded in 2012 by Oren and Roni Frank, Talkspace connects users with licensed therapists and psychiatrists through web and mobile platforms. The service offers communication through text, audio, and video messaging, as well as live video sessions in some cases. The company is headquartered in New York City.

MED vs TALK — Head-to-Head

Bigger by revenue
MED
MED
1.2× larger
MED
$75.1M
$63.0M
TALK
Growing faster (revenue YoY)
TALK
TALK
+66.2% gap
TALK
29.3%
-36.9%
MED
Faster 2-yr revenue CAGR
TALK
TALK
Annualised
TALK
17.8%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
TALK
TALK
Revenue
$75.1M
$63.0M
Net Profit
$4.8M
Gross Margin
69.4%
Operating Margin
-10.4%
6.1%
Net Margin
7.6%
Revenue YoY
-36.9%
29.3%
Net Profit YoY
292.5%
EPS (diluted)
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
TALK
TALK
Q4 25
$75.1M
$63.0M
Q3 25
$89.4M
$59.4M
Q2 25
$105.6M
$54.3M
Q1 25
$115.7M
$52.2M
Q4 24
$119.0M
$48.7M
Q3 24
$140.2M
$47.4M
Q2 24
$168.6M
$46.1M
Q1 24
$174.7M
$45.4M
Net Profit
MED
MED
TALK
TALK
Q4 25
$4.8M
Q3 25
$-2.3M
$3.3M
Q2 25
$2.5M
$-541.0K
Q1 25
$-772.0K
$318.0K
Q4 24
$1.2M
Q3 24
$1.1M
$1.9M
Q2 24
$-8.2M
$-474.0K
Q1 24
$8.3M
$-1.5M
Gross Margin
MED
MED
TALK
TALK
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
44.6%
Q4 24
74.1%
44.2%
Q3 24
75.4%
45.6%
Q2 24
73.2%
45.5%
Q1 24
72.8%
47.8%
Operating Margin
MED
MED
TALK
TALK
Q4 25
-10.4%
6.1%
Q3 25
-4.6%
3.7%
Q2 25
-1.0%
-3.3%
Q1 25
-1.1%
-2.1%
Q4 24
0.6%
1.2%
Q3 24
1.5%
0.2%
Q2 24
-4.7%
-7.6%
Q1 24
4.5%
-3.7%
Net Margin
MED
MED
TALK
TALK
Q4 25
7.6%
Q3 25
-2.5%
5.5%
Q2 25
2.3%
-1.0%
Q1 25
-0.7%
0.6%
Q4 24
2.5%
Q3 24
0.8%
4.0%
Q2 24
-4.8%
-1.0%
Q1 24
4.8%
-3.2%
EPS (diluted)
MED
MED
TALK
TALK
Q4 25
$-1.64
Q3 25
$-0.21
$0.02
Q2 25
$0.22
Q1 25
$-0.07
$0.00
Q4 24
$0.08
$0.01
Q3 24
$0.10
$0.01
Q2 24
$-0.75
$0.00
Q1 24
$0.76
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
TALK
TALK
Cash + ST InvestmentsLiquidity on hand
$167.3M
$37.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$198.9M
$117.0M
Total Assets
$248.0M
$134.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
TALK
TALK
Q4 25
$167.3M
$37.4M
Q3 25
$173.5M
$39.5M
Q2 25
$162.7M
$54.3M
Q1 25
$164.6M
$60.1M
Q4 24
$162.3M
$76.7M
Q3 24
$170.0M
$119.0M
Q2 24
$163.5M
$114.9M
Q1 24
$156.4M
$120.3M
Stockholders' Equity
MED
MED
TALK
TALK
Q4 25
$198.9M
$117.0M
Q3 25
$214.7M
$109.1M
Q2 25
$216.0M
$112.9M
Q1 25
$211.0M
$113.4M
Q4 24
$210.1M
$117.4M
Q3 24
$207.3M
$117.6M
Q2 24
$205.3M
$114.0M
Q1 24
$211.0M
$119.6M
Total Assets
MED
MED
TALK
TALK
Q4 25
$248.0M
$134.9M
Q3 25
$268.2M
$129.1M
Q2 25
$269.3M
$132.8M
Q1 25
$280.0M
$134.2M
Q4 24
$284.2M
$138.7M
Q3 24
$291.2M
$138.2M
Q2 24
$293.5M
$133.8M
Q1 24
$302.8M
$138.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
TALK
TALK
Operating Cash FlowLast quarter
$-5.3M
$5.4M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
1.13×
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
TALK
TALK
Q4 25
$-5.3M
$5.4M
Q3 25
$12.1M
$4.7M
Q2 25
$-3.4M
$-351.0K
Q1 25
$3.4M
$-1.2M
Q4 24
$-4.9M
$3.7M
Q3 24
$9.1M
$6.2M
Q2 24
$13.1M
$4.8M
Q1 24
$7.3M
$-3.4M
Free Cash Flow
MED
MED
TALK
TALK
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
$4.5M
Q1 24
$5.4M
$-3.8M
FCF Margin
MED
MED
TALK
TALK
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
9.7%
Q1 24
3.1%
-8.3%
Capex Intensity
MED
MED
TALK
TALK
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
0.7%
Q1 24
1.1%
0.8%
Cash Conversion
MED
MED
TALK
TALK
Q4 25
1.13×
Q3 25
1.46×
Q2 25
-1.36×
Q1 25
-3.90×
Q4 24
3.02×
Q3 24
8.04×
3.31×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MED
MED

Segment breakdown not available.

TALK
TALK

Payor Revenue$47.7M76%
Dte Revenue$11.6M18%
Consumer$3.7M6%

Related Comparisons